Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Viacyte Inc.
Headquarters: San Diego, CA, United States of America
Website: N/A
Year Founded: 1999
Status: Acquired
BioCentury | Sep 10, 2024
Management Tracks
Vir names Jason O’Byrne CFO
Plus: Maslowski to become CEO of Forge as Miller steps down, and updates from Sofinnova Partners, Abingworth, PATH and more
BioCentury | Aug 6, 2024
Finance
With an eye toward ‘inflection capital’ for biotechs, TPG focuses new fund on clinical POC
Firm has $580M in to invest in life sciences strategy
BioCentury | Jan 9, 2024
Deals
Jan. 8 Quick Takes: Novartis taps China-based Argo for RNAi deal
Plus: Venrock unveils $650M fund and more from Calypso, Isomorphic, Bayer, Flagship and Vertex
BioCentury | Sep 15, 2023
Management Tracks
O’Callaghan to lead Deep Genomics as CEO
Plus: Pliant hires Kuo and updates for Helsinn Group, Sling, Repairon, Nusano and Fractyl
BioCentury | Jul 7, 2023
Management Tracks
Zai promotes Chen to CFO
Plus: Chiesi elevates next generation, Lang now Lyell’s CBO and updates from OrbiMed, Gimv, Nkarta, InflaRx, Akamis and more
BioCentury | May 3, 2023
Data Byte
Vertex continues deal streak to add modalities and indications
The large cap has committed at least $8.6B in 17 deals since 2020
BioCentury | Feb 3, 2023
Management Tracks
Graham named CEO of Roche Pharmaceuticals
Plus: Goswami becomes CFO at Illumina, and updates from SOBI, BDGene, Nordic and more
BioCentury | Jul 11, 2022
Deals
Vertex adds to Type I diabetes cell therapy ambitions with $320M ViaCyte takeout
Acquisition adds tools, IP to accelerate VX-880, plus ViaCyte’s own islet cell therapy pipeline
BioCentury | May 18, 2022
Deals
May 17 Quick Takes: Abeona licenses gene therapy to Ultragenyx
Plus Evotec, Sernova partner in diabetes and updates from Mirvie, Cytokinetics, Kallyope, Sosei and more
BioCentury | Apr 20, 2022
Emerging Company Profile
Satellite: cell therapy implants for any outpost in the body
Led by AveXis vet Lennon, Boston area biotech raises $110M with backing from series A lead aMoon to develop cell-based tissue therapies
Items per page:
1 - 10 of 54